Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein... Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. Its lead product candidate is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received organ transplants. 더 보기
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1299 | -81.1875 | 0.16 | 0.16 | 0.0301 | 3763237 | 0.06736288 | CS |
4 | -0.1589 | -84.0740740741 | 0.189 | 0.1969 | 0.0301 | 1640321 | 0.10129022 | CS |
12 | -0.1358 | -81.8565400844 | 0.1659 | 0.257406 | 0.0301 | 2699096 | 0.16596214 | CS |
26 | -0.3999 | -93 | 0.43 | 0.56 | 0.0301 | 1888794 | 0.20428837 | CS |
52 | -0.5899 | -95.1451612903 | 0.62 | 1.31 | 0.0301 | 997325 | 0.23308021 | CS |
156 | -2.4199 | -98.7714285714 | 2.45 | 5.75 | 0.0301 | 447037 | 0.77651072 | CS |
260 | -16.7299 | -99.8204057279 | 16.76 | 18.24 | 0.0301 | 404370 | 2.0569835 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관